orlistat

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	9.22 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Steatorrhoea	180.56	16.95	32	6649	536	90621230
Cerebral venous thrombosis	99.75	16.95	25	6656	2303	90619463
Drug interaction	83.15	16.95	102	6579	276351	90345415
Thalamic infarction	74.83	16.95	15	6666	497	90621269
Cholelithiasis	64.52	16.95	43	6638	52463	90569303
Abdominal pain	59.09	16.95	105	6576	395616	90226150
Rectal discharge	55.91	16.95	13	6668	872	90620894
Acute hepatic failure	44.46	16.95	25	6656	22536	90599230
Rectal haemorrhage	43.31	16.95	41	6640	82703	90539063
Crystal nephropathy	42.61	16.95	11	6670	1140	90620626
Jaundice	40.83	16.95	27	6654	32490	90589276
Virologic failure	39.69	16.95	12	6669	2212	90619554
Kidney fibrosis	39.64	16.95	12	6669	2222	90619544
Oxalosis	37.09	16.95	6	6675	56	90621710
Hyperoxaluria	36.48	16.95	7	6674	184	90621582
Menopausal symptoms	35.86	16.95	12	6669	3066	90618700
Slow response to stimuli	33.50	16.95	9	6672	1087	90620679
Haematochezia	31.26	16.95	32	6649	70881	90550885
Abdominal pain upper	30.24	16.95	72	6609	332602	90289164
Renal tubular atrophy	30.07	16.95	8	6673	932	90620834
Nephropathy	29.02	16.95	14	6667	9221	90612545
Urine oxalate increased	28.93	16.95	6	6675	236	90621530
Crying	26.76	16.95	19	6662	25626	90596140
Dysarthria	26.61	16.95	26	6655	54456	90567310
Pancreatitis	26.33	16.95	29	6652	69797	90551969
Liver function test abnormal	26.22	16.95	25	6656	50820	90570946
Muscle spasticity	25.47	16.95	21	6660	35301	90586465
Oropharyngeal blistering	24.66	16.95	7	6674	1036	90620730
Pregnancy on oral contraceptive	24.20	16.95	7	6674	1108	90620658
Hepatic encephalopathy	23.76	16.95	14	6667	13758	90608008
Ear pain	23.56	16.95	25	6656	57677	90564089
Liver iron concentration abnormal	23.10	16.95	4	6677	58	90621708
Pancreatitis acute	22.96	16.95	19	6662	32096	90589670
Drug intolerance	22.87	16.95	3	6678	447588	90174178
Circulatory collapse	22.69	16.95	17	6664	24887	90596879
Lactic acidosis	22.65	16.95	23	6658	50440	90571326
Bradyphrenia	22.30	16.95	11	6670	7601	90614165
Acute kidney injury	21.57	16.95	62	6619	320325	90301441
Gallbladder disorder	21.42	16.95	15	6666	19788	90601978
Alanine aminotransferase increased	21.02	16.95	34	6647	118304	90503462
Diverticulitis	21.02	16.95	21	6660	45166	90576600
Abortion spontaneous	19.60	16.95	22	6659	54034	90567732
Nephrosclerosis	19.55	16.95	6	6675	1163	90620603
Chromaturia	19.52	16.95	14	6667	19173	90602593
Depressed mood	19.17	16.95	21	6660	50201	90571565
Vanishing bile duct syndrome	18.60	16.95	6	6675	1366	90620400
Faeces discoloured	18.20	16.95	14	6667	21306	90600460
Psychomotor retardation	17.32	16.95	8	6673	4781	90616985
Transposition of the great vessels	17.19	16.95	4	6677	269	90621497
Breast enlargement	17.15	16.95	6	6675	1749	90620017
Flatulence	17.02	16.95	18	6663	41349	90580417

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephropathy	48.19	25.63	15	1383	6896	42613041
Blood uric acid increased	36.31	25.63	15	1383	15532	42604405
Hyperoxaluria	35.91	25.63	6	1392	164	42619773
Sleep apnoea syndrome	28.54	25.63	14	1384	21594	42598343
Coronary artery disease	25.69	25.63	18	1380	53702	42566235

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Steatorrhoea	99.57	17.81	21	7040	1040	110581198
Cerebral venous thrombosis	94.95	17.81	25	7036	3237	110579001
Cholelithiasis	84.95	17.81	52	7009	63370	110518868
Hyperoxaluria	68.97	17.81	13	7048	360	110581878
Nephropathy	63.54	17.81	26	7035	13441	110568797
Thalamic infarction	62.47	17.81	15	7046	1337	110580901
Drug interaction	59.67	17.81	111	6950	500072	110082166
Crystal nephropathy	57.75	17.81	15	7046	1841	110580397
Abdominal pain	49.28	17.81	104	6957	512885	110069353
Rectal discharge	44.98	17.81	11	7050	1058	110581180
Acute hepatic failure	44.01	17.81	28	7033	36440	110545798
Kidney fibrosis	41.04	17.81	14	7047	4378	110577860
Menopausal symptoms	40.00	17.81	12	7049	2489	110579749
Oxalosis	39.46	17.81	7	7054	137	110582101
Urine oxalate increased	36.25	17.81	7	7054	221	110582017
Abdominal pain upper	33.72	17.81	71	6990	349040	110233198
Renal tubular atrophy	32.47	17.81	10	7051	2266	110579972
Ear pain	32.40	17.81	27	7034	53199	110529039
Jaundice	29.89	17.81	27	7034	59209	110523029
Slow response to stimuli	29.48	17.81	9	7052	1979	110580259
Vomiting	29.14	17.81	125	6936	910550	109671688
Rectal haemorrhage	29.03	17.81	37	7024	119796	110462442
Muscle spasticity	27.83	17.81	21	7040	35894	110546344
Crying	26.82	17.81	18	7043	25610	110556628
Pancreatitis	24.44	17.81	30	7031	93503	110488735
Pneumonia	24.13	17.81	13	7048	876701	109705537
Liver iron concentration abnormal	23.68	17.81	4	7057	58	110582180
Off label use	22.89	17.81	38	7023	1500147	109082091
Diverticulitis	22.41	17.81	22	7039	53500	110528738
Hepatic steatosis	22.20	17.81	21	7040	48810	110533428
Oropharyngeal blistering	21.80	17.81	6	7055	917	110581321
Pregnancy on oral contraceptive	21.77	17.81	6	7055	922	110581316
Sleep apnoea syndrome	21.52	17.81	19	7042	40428	110541810
Faeces pale	21.18	17.81	8	7053	3349	110578889
Dysarthria	20.41	17.81	26	7035	84095	110498143
Pancreatitis acute	20.23	17.81	22	7039	60252	110521986
Gallbladder disorder	20.18	17.81	14	7047	21015	110561223
Lip swelling	19.69	17.81	20	7041	50647	110531591
Bradyphrenia	19.32	17.81	11	7050	11717	110570521
Hepatitis acute	19.20	17.81	13	7048	18753	110563485
Blood triglycerides increased	18.55	17.81	14	7047	23912	110558326
Death	18.30	17.81	11	7050	698858	109883380
Breast enlargement	18.22	17.81	6	7055	1683	110580555
Diarrhoea	17.86	17.81	129	6932	1139376	109442862

Source	Code	Description
ATC	A08AB01	ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Peripherally acting antiobesity products
FDA MoA	N0000009916	Lipase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019440	Anti-Obesity Agents
MeSH PA	D057847	Lipid Regulating Agents
FDA EPC	N0000175591	Intestinal Lipase Inhibitor
CHEBI has role	CHEBI:65001	EC 3.1.1.3 (triacylglycerol lipase) inhibitor
CHEBI has role	CHEBI:71476	EC 2.3.1.85 (fatty acid synthase) inhibitor
CHEBI has role	CHEBI:74518	anti-obesity agent
CHEBI has role	CHEBI:76969	bacterial metabolite

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

orlistat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Disease	Relation	SNOMED_ID	DOID
Obesity	indication	414916001	DOID:9970
Primary hyperoxaluria	contraindication	17901006	DOID:2977
Obstruction of bile duct	contraindication	30144000
Anorexia nervosa	contraindication	56882008	DOID:8689
Hepatic failure	contraindication	59927004
Bulimia nervosa	contraindication	78004001
Vitamin deficiency	contraindication	85670002
Hepatic necrosis	contraindication	87248009
Liver function tests abnormal	contraindication	166603001
Drug-induced hepatitis	contraindication	235876009
Malabsorption States	contraindication
Calcium Oxalate Renal Calculi	contraindication

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Pancreatic triacylglycerol lipase	Enzyme	P16233	LIPP_HUMAN	INHIBITOR	IC50	8.90	IUPHAR	DRUG LABEL
Gastric triacylglycerol lipase	Enzyme	P07098	LIPG_HUMAN	INHIBITOR			CHEMBL	DRUG LABEL
Fatty acid synthase	Enzyme	P49327	FAS_HUMAN		IC50	5.33	CHEMBL
Sn1-specific diacylglycerol lipase alpha	Enzyme	Q9Y4D2	DGLA_HUMAN		IC50	8	CHEMBL
Sn1-specific diacylglycerol lipase beta	Enzyme	Q8NCG7	DGLB_HUMAN		IC50	7.22	CHEMBL
Abhydrolase domain-containing protein 16A	Enzyme	O95870	ABHGA_HUMAN		IC50	7.52	CHEMBL
Monoacylglycerol lipase ABHD12	Enzyme	Q8N2K0	ABD12_HUMAN		IC50	7.10	CHEMBL
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN		Ki	5.60	CHEMBL
Monoacylglycerol lipase ABHD6	Enzyme	Q9BV23	ABHD6_HUMAN		IC50	7.32	CHEMBL
Hepatic triacylglycerol lipase	Enzyme	P11150	LIPC_HUMAN		IC50	8.52	CHEMBL
Endothelial lipase	Enzyme	Q9Y5X9	LIPE_HUMAN		IC50	8.22	CHEMBL
Platelet-activating factor acetylhydrolase	Enzyme	Q13093	PAFA_HUMAN		IC50	7.30	CHEMBL
Lipoprotein lipase	Enzyme	P06858	LIPL_HUMAN		IC50	7.18	CHEMBL
Fatty-acid amide hydrolase 1	Enzyme		FAAH1_RAT		IC50	8	CHEMBL
Pancreatic triacylglycerol lipase	Enzyme		LIPP_PIG		IC50	6.66	CHEMBL
Sn1-specific diacylglycerol lipase alpha	Enzyme		DGLA_MOUSE		IC50	7.70	CHEMBL

ID	Source
4021159	VUID
N0000148610	NUI
D04028	KEGG_DRUG
4021159	VANDF
C0076275	UMLSCUI
CHEBI:94686	CHEBI
CHEMBL175247	ChEMBL_ID
D000077403	MESH_DESCRIPTOR_UI
DB01083	DRUGBANK_ID
5277	IUPHAR_LIGAND_ID
6318	INN_ID
95M8R751W8	UNII
3034010	PUBCHEM_CID
226918	RXNORM
109396	MMSL
186669	MMSL
29932	MMSL
8088	MMSL
d04429	MMSL
007654	NDDF
116093009	SNOMEDCT_US
387007000	SNOMEDCT_US
95M8R751W8	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ALLI	HUMAN OTC DRUG LABEL	1	0135-0461	CAPSULE	60 mg	ORAL	NDA	17 sections
Xenical	HUMAN PRESCRIPTION DRUG LABEL	1	61269-460	CAPSULE	120 mg	ORAL	NDA	31 sections
ORLISTAT	HUMAN PRESCRIPTION DRUG LABEL	1	61269-565	CAPSULE	120 mg	ORAL	NDA authorized generic	31 sections
ALLI	HUMAN OTC DRUG LABEL	1	71610-805	CAPSULE	60 mg	ORAL	NDA	17 sections